QIAGEN (NYSE:QGEN) Stock Rating Reaffirmed by Berenberg Bank

QIAGEN (NYSE:QGEN)‘s stock had its “buy” rating reiterated by analysts at Berenberg Bank in a research report issued on Friday, The Fly reports.

Other equities analysts have also issued reports about the company. DZ Bank reiterated a “neutral” rating on shares of QIAGEN in a research report on Wednesday, April 7th. Zacks Investment Research downgraded shares of QIAGEN from a “buy” rating to a “hold” rating and set a $54.00 price target on the stock. in a research note on Friday, April 9th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of QIAGEN in a research note on Tuesday. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of QIAGEN in a research report on Tuesday, May 4th. Finally, Kepler Capital Markets restated a “buy” rating on shares of QIAGEN in a research report on Friday, April 2nd. Six equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. QIAGEN has a consensus rating of “Buy” and a consensus target price of $59.04.

Shares of NYSE:QGEN traded down $0.13 during trading on Friday, reaching $47.59. The company had a trading volume of 8,345 shares, compared to its average volume of 808,372. The company has a fifty day moving average price of $48.94. The company has a debt-to-equity ratio of 0.68, a current ratio of 3.34 and a quick ratio of 2.70. The stock has a market cap of $10.85 billion, a PE ratio of 24.79, a P/E/G ratio of 1.13 and a beta of 0.25. QIAGEN has a 12 month low of $42.22 and a 12 month high of $59.00.

QIAGEN (NYSE:QGEN) last announced its earnings results on Sunday, May 2nd. The company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.63 by $0.03. QIAGEN had a net margin of 21.72% and a return on equity of 21.06%. The company had revenue of $567.21 million during the quarter, compared to analyst estimates of $557.57 million. During the same period in the previous year, the business earned $0.34 earnings per share. As a group, equities research analysts predict that QIAGEN will post 2.48 EPS for the current year.

A number of large investors have recently made changes to their positions in QGEN. Tompkins Financial Corp purchased a new stake in QIAGEN in the 4th quarter worth approximately $32,000. Captrust Financial Advisors bought a new position in shares of QIAGEN during the first quarter valued at approximately $38,000. Bank Julius Baer & Co. Ltd Zurich bought a new position in shares of QIAGEN during the fourth quarter valued at approximately $43,000. RWM Asset Management LLC purchased a new stake in QIAGEN in the first quarter worth $49,000. Finally, Ellevest Inc. boosted its holdings in QIAGEN by 91.1% in the fourth quarter. Ellevest Inc. now owns 1,158 shares of the company’s stock valued at $61,000 after acquiring an additional 552 shares in the last quarter. Institutional investors own 52.07% of the company’s stock.

QIAGEN Company Profile

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.

See Also: Trading signals using Bollinger bands

The Fly logo

Analyst Recommendations for QIAGEN (NYSE:QGEN)

Receive News & Ratings for QIAGEN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QIAGEN and related companies with MarketBeat.com's FREE daily email newsletter.